Loading...
XNAS
NVAX
Market cap1.80bUSD
Oct 08, Last price  
11.01USD
1D
-1.87%
1Q
18.01%
Jan 2017
-56.31%
Name

Novavax Inc

Chart & performance

D1W1MN
XNAS:NVAX chart
P/E
4.11
P/S
1.61
EPS
2.68
Div yield, %
—
Shrs. gr., 5y
24.64%
Rev. gr., 5y
118.83%
Revenues
1.12b
+64.69%
4,683,0001,513,0001,064,000325,000343,00014,688,00022,076,00020,915,00030,659,00036,250,00015,353,00031,176,00034,288,00018,662,00022,388,000197,581,0001,598,951,000556,382,000682,162,0001,123,479,000
Net income
440m
P
-23,068,000-34,765,000-36,049,000-38,374,000-35,708,000-19,364,000-28,507,000-51,983,000-82,947,000-156,937,000-279,966,000-183,769,000-184,748,000-130,102,000-418,259,000-1,743,751,000-657,939,000-545,062,000-187,499,000440,302,000
CFO
-245m
L+180.34%
-14,810,000-26,742,000-24,310,000-32,830,000-32,852,000-23,629,000-18,229,000-45,359,000-67,014,000-126,090,000-255,467,000-138,696,000-184,825,000-136,623,000-42,541,000322,946,000-415,937,000-713,967,000-87,263,000-244,635,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine. It has license and collaboration agreements with Sanofi, Pfizer Inc., Takeda Pharmaceutical Company Limited, and Serum Life Sciences Limited for the to develop, manufacture, and commercialize the COVID-19 vaccine. The company was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Key people

Gregory M. Glenn
President, Research and Development · since 2016
Bob Darius
Senior Vice President - Quality Operations · since 2016
Amy B. Fix
Senior Vice President - Regulatory Affairs · since 2016
Brian Rosen
Senior Vice President - Commercial Strategy · since 2018
Jeffrey Stoddard
Vice President - Medical Affairs · since 2016
John J. Trizzino
Senior Vice President, Chief Business Officer, Chief Financial Officer and Treasurer · since 2018
John A. Herrmann
Senior Vice President, General Counsel, Corporate Secretary · since 2014
Stanley C. Erck
President, Chief Executive Officer, Director · since 2011
Rajiv I. Modi
Director · since 2009
James Francis Young
Independent Chairman of the Board · since 2011
Richard Douglas
Independent Director · since 2010
Gary Evans
Independent Director · since 2011
Rachel K. King
Independent Director · since 2018
URL
https://www.novavax.com/
IPO date
May 16, 1973
Employees
1,992
Domiciled in
US
Incorporated in
US
Legal address
C/O CORPORATION SERVICE COMPANY
251 LITTLE FALLS DRIVE
WILMINGTON, DE 19808
US
Headquarters
21 Firstfield Road
Gaithersburg, MD 20878
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT